Price
No data yet.
Social Signal Score
Revenue
$1.63M+408.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alex Duggan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.00
- Country
- GB
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -29.42
Financials
Revenue
$1.63M+408.6%Net Income
$-1.19MEBITDA
$-1.25MFree Cash Flow
$-2.17MEPS (diluted)
$-0.00Shares Outstanding (diluted)
581.33M+650.1%Operating Expenses
$2.88MCash & Debt
$1.24MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.70M | $-9.07M | $-0.03 |
| 2024 | $13.93M | $1.29M | $0.00 |
| 2023 | $3.10M | $-6.51M | $-0.02 |
| 2022 | $0.00 | $-5.85M | $-0.02 |
| 2021 | $0.00 | $-4.96M | $-0.02 |
| 2020 | $0.00 | $-2.41M | $-0.01 |
| 2019 | $31.8K | $-8.92M | $-0.04 |
| 2018 | $0.00 | $-5.88M | $-0.04 |
| 2017 | $362.7K | $-3.90M | $-0.03 |
| 2016 | $170.4K | $-3.70M | $-0.04 |
| 2015 | $29.5K | $-5.08M | $-0.05 |
| 2014 | $43.9K | $-3.00M | $-0.03 |
| 2013 | $370.9K | $-2.21M | $-0.03 |
| 2012 | $75.0K | $-2.18M | $-0.03 |
Valuation
FAMDFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsproactiveinvestors.com·10d ago·Neutral
Futura Medical revises sale timetable as finance director steps down Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare group behind Eroxon, has revised its formal sale timetable as finance director and chief operating officer Angela Hildreth prepares to step down from her executive roles. The board now expects to invite interested parties to submit non-binding offers over the next four weeks, rather than the previously stated submission date of 2 October.
View source ↗ - Newsproactiveinvestors.com·11d ago·Neutral
Futura Medical plans 2027 Eroxon Intense launch after positive test Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, reported positive results from an additional Eroxon Intense home user test ahead of a planned launch in the first half of 2027. The test involved 115 men aged 18 to 59, most with mild to moderate erectile dysfunction.
View source ↗ - Newsproactiveinvestors.co.uk·41d ago·Positive
Futura Medical upsizes retail offer after strong investor demand Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, has increased the size of its retail share offer after strong demand from investors. The retail offer closed on Friday, having attracted applications well beyond the company's original target.
View source ↗ - Newsproactiveinvestors.co.uk·45d ago·Positive
Futura Medical launches formal sale process alongside £1.6m placing Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the sexual health group behind the Eroxon erectile dysfunction gel, has begun a formal process that could see the sale of the business, or its assets. The move comes alongside a placing and subscription to raise approximately £1.6 million, which should fund it through to the conclusion of negotiations.
View source ↗ - Newsproactiveinvestors.co.uk·47d ago·Neutral
Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review. The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market Performance Group as its new US commercial partner from 1 September, replacing Haleon after a two-month transition.
View source ↗
Earnings
Wed, Apr 14(in 6 months)
Estimates and results for FAMDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in FAMDF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.